feeds

30.07.2019
2019

The EMCDDA has published today its latest update on Drug-related deaths and mortality in Europe. The information provided in the report is collected through the EMCDDA’s expert network on drug-related deaths (DRD). The updates presented shed light on important public health challenges faced by European policymakers and stakeholders, with regard to monitoring, prevention, risk assessment, harm reduction and drug treatment. Below are some of the findings ‘At a glance’.

2019

This publication provides an update on drug-related deaths in Europe, presenting and analysing the latest data and trends in drug-induced deaths and overall mortality among high-risk drug users in the European Union and beyond. It draws on contributions from specialists representing more than 40 countries at the latest meeting of the EMCDDA expert network on drug-related deaths in November 2018 as well as information provided by European countries in the annual reporting exercise.

2019

Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs (PWID) in Europe. However, currently HCV infection is both preventable and curable. The importance of targeting PWID as a key population for the elimination of hepatitis C in Europe and promoting their access to testing and all other elements of the cascade of care is highlighted in European and national hepatitis C policies.

26.07.2019
2019

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day. Its aim is to increase awareness and understanding of viral hepatitis and the diseases it causes.The introduction of direct-acting antiviral (DAA) therapy has profoundly changed and improved the clinical management of hepatitis C virus (HCV) infection and given impetus to the WHO goal of eliminating HCV infection as a public health threat by 2030.

24.07.2019
2019

Representatives of the EMCDDA and the General directorate for drug control of the Ministry of internal affairs of the Russian Federation are meeting in Moscow to discuss and exchange views on the drug situation in the European Union and the Russian Federation. The meeting marks EMCDDA Director Alexis Goosdeel’s first official visit to Russia, and is a follow-up to a Russian official visit to the EMCDDA in September last year.

18.07.2019
2019

EMCDDA Director Alexis Goosdeel is paying his first official visit to Montenegro this week where he will meet high-level dignitaries working in the drugs field. Over two days (17–18 July), an EMCDDA delegation will meet: 

17.07.2019
2019

Italy’s highest court says low-THC cannabis cannot be sold

10.07.2019
2019

His Excellency the President of the Portuguese Republic, Marcelo Rebelo de Sousa visited the EU drugs agency (EMCDDA) today for an insight into the work of the agency and the latest trends and developments in the drug situation in Europe. This was the President’s first visit to the EMCDDA since he took office.

2019

The profile presents the structure, objectives and working methods of the Serbian national early warning system. It describes functions of the institutions participating in the early warning system and mentions data collection tools. It was prepared within the EMCDDA-IPA6 project ‘Stepwise integration of the IPA beneficiaries in the activities of the EMCDDA and the Reitox Network’ funded by the European Commission.

02.07.2019
2019

This content was published in the first EU4MD update released on 3.7.2019. This update also presents a section on partnerships and related activities, upcoming events, and a research corner.

2019

These are the EMCDDA's final annual accounts for the financial year 2018.

01.07.2019
2019

The EMCDDA is collaborating this week in the 2019 International Conference on Drug Prevention, Treatment and Care — Inspiration and Direction, organised in Vienna by the International Society of Substance Use Prevention and Treatment Professionals (ISSUP). The event — running from 1–5 July with a packed programme of plenaries, keynotes and training workshops — brings together national and international experts in substance use prevention, treatment and care.

28.06.2019
2019

The EMCDDA has published today its latest update on Drug-related infectious diseases in Europe for the period to February 2019. The publication provides an overview of the most recent infectious disease surveillance data, outbreak investigations and prevention and control measures among people who inject drugs (PWID) in Europe. The information presented is collected through the EMCDDA’s drug-related infectious diseases (DRID) network. Below are some of the findings ‘At a glance’.

2019

This report presents an overview of infectious diseases among people who inject drugs in Europe, both in the community and in prison settings, covering disease surveillance, outbreak investigations, and prevention and control, for the period up to the end of February 2019. The report describes the population at risk, in terms of the number of injectors and the main injecting practices, presenting the latest data on incidence and prevalence of drug-related hepatitis C and B virus and HIV infections, as well as recent outbreaks, among people who inject drugs in Europe.

26.06.2019
2019

This content was published in the Best pratice portal update briefing on 27.06.2019

25.06.2019
2019

Cannabis products have become increasingly diverse in Europe and close monitoring of their potency and potential health effects is essential. These are among the conclusions of a new report published today by the EU drugs agency (EMCDDA) ahead of International day against drug abuse and illicit trafficking (26 June) (1).

2019

This paper provides an overview of established and emerging cannabis products in Europe. For each type of product, major issues in its production, distribution, use and effects on health are detailed. In doing so, the paper seeks to inform a discussion of the new challenges that may emerge in the monitoring of these products and the consequences of their use.

14.06.2019
2019

An external evaluation of the EMCDDA, new products and services, and support to policy and practice in the fields of health and security are among the features presented in the latest General Report of Activities published today by the agency. The report, covering key achievements and governance in 2018, presents the implementation of the EMCDDA work programme activities over the 12-month period.

2019

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

06.06.2019
2019

Europe is seeing signs of an increase in cocaine availability, with seizures of the drug at record levels. This is according to the European Drug Report 2019: Trends and Developments, released by the EU drugs agency (EMCDDA) today in Brussels (1).

2019

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug Report package.

Take our survey

2019

Available in English and Slovak, this report presents the top-level overview of the drug phenomenon in Slovakia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Luxembourg, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2019

This report presents the top-level overview of the drug phenomenon in Greece, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Turkey, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Italy, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in the Netherlands, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Latvia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Slovenia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2019

This report presents the top-level overview of the drug phenomenon in Croatia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2017 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

Loading